Table 1 Clinical parameters, CBC and immunophenotypic markers of CLL patients
Characteristics | CLL patients (n = 35) |
|---|---|
Age, mean (range) | 64.34 (36–86 years) |
Gender, n (%) | |
Male | 24 (68.6%) |
Female | 11 (31.4%) |
Rai staging system, n (%) | |
0 | 8 (22.9%) |
I | 3 (8.6%) |
II | 3 (8.6%) |
III | 10 (28.6%) |
IV | 11 (31.4%) |
Modified Rai staging system, n (%) | |
Low-risk group | 8 (22.9%) |
Intermediate-risk group | 6 (17.1%) |
High-risk group | 21 (60.0%) |
Binet staging system, n (%) | |
A | 12 (34.3%) |
B | 2 (5.7%) |
C | 21 (60.0%) |
Splenomegaly, n (%) | |
Yes | 19 (54.3%) |
No | 16 (45.7%) |
Lymphadenopathy, n (%) | |
Yes | 11 (31.4%) |
No | 24 (68.6%) |
Hepatomegaly, n (%) | |
Yes | 0 (0%) |
No | 35 (100%) |
WBC count × 103/μL, median (IQR) | 45 (22–112) |
Platelets × 103/μL, median (IQR) | 131 (95–167) |
≥ 100 | n, 24 (68.6%) |
< 100 | n, 11 (31.4%) |
Hemoglobin g/dL, median (IQR) | 10.7 (9.9–13.2) |
≥ 11 | n, 15 (42.9%) |
< 11 | n, 20 (57.1%) |
ALC × 103/μL, median (IQR) | 35.9 (18.4–101) |
ANC × 103/μL, median (IQR) | 4.2 (3.6–11) |
PLR × 103/μL, median (IQR) | 3.2 (1.3–8.1) |
NLR × 103/μL, median (IQR) | 0.15 (0.09–0.18) |
CD38 (%), median (IQR) | 3.0 (1.0–6.0) |
CD25 (%), median (IQR) | 6.0 (1.5–10.0) |
Double positive CD56/CD117, median (IQR) | 0.1 (0.1–0.4) |